Table 2:
Outcome measures
| Parameter | No. |
|---|---|
| No. of Pipelines | |
| 1 | 255 (77.5%) |
| 2 | 52 (15.8%) |
| ≥3 | 22 (6.7%) |
| Platelet function test | |
| Yes | 316 (96%) |
| No | 13 (4%) |
| Clopidogrel responder | |
| Yes | 228 (72.2%) |
| No | 88 (27.8%) |
| Nonresponders' treatment | |
| Switch to ticagrelor | 27 (30.7%) |
| Clopidogrel boost | 39 (44.3%) |
| Same dose of clopidogrel | 22 (25%) |
| Last angiographic follow-up (median) (range) (mo) | 13.5 (1–83) |
| Follow-up occlusion rate | |
| Complete (100%) | 297 (78.2%) |
| Near-complete (90%–99%) | 29 (7.6%) |
| Partial (<90%) | 54 (14.2%) |
| Retreatment | |
| Endovascular | 24 (6.3%) |
| Posttreatment mRS | |
| 0–2 | 314 (95.6%) |
| 3–5 | 11 (3.3%) |
| 6 (Death) | 4 (1.2%) |
| Follow-up mRS | |
| Improved | 110 (33.4%) |
| No change | 190 (57.8%) |
| Worsened | 29 (8.8%) |
| Neurologic complications | |
| Thromboembolic | 31 (9.4%) |
| Symptomatic | 17 (5.2%) |
| Hemorrhagic | 11 (3.3%) |
| Symptomatic | 6 (1.8%) |